Ishikawa H - Search Results

1

Application of conditional probability analysis to distant metastases from lung cancer.

Oikawa A, Takahashi H, Ishikawa H, Kurishima K, Kagohashi K, Satoh H. Oikawa A, et al. Among authors: ishikawa h. Oncol Lett. 2012 Mar;3(3):629-634. doi: 10.3892/ol.2011.535. Epub 2011 Dec 23. Oncol Lett. 2012. PMID: 22740965 Free PMC article.

2

Cut-off levels of NSE to differentiate SCLC from NSCLC.

Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K. Satoh H, et al. Among authors: ishikawa h. Oncol Rep. 2002 May-Jun;9(3):581-3. Oncol Rep. 2002. PMID: 11956631

3

Spontaneous regression of pulmonary bullae.

Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Satoh H, et al. Among authors: ishikawa h. Australas Radiol. 2002 Mar;46(1):106-7. doi: 10.1046/j.1440-1673.2001.01005.x. Australas Radiol. 2002. PMID: 11966599

4

Japanese herbal medicine in patients with advanced lung cancer: prolongation of survival.

Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Satoh H, et al. Among authors: ishikawa h. J Altern Complement Med. 2002 Apr;8(2):107-8. doi: 10.1089/107555302317371370. J Altern Complement Med. 2002. PMID: 12006117 No abstract available.

5

Pleural to serum CEA ratio in lung adenocarcinoma.

Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Satoh H, et al. Among authors: ishikawa h. Clin Oncol (R Coll Radiol). 2002 Apr;14(2):178-9. doi: 10.1053/clon.2002.0051. Clin Oncol (R Coll Radiol). 2002. PMID: 12069128 No abstract available.

6

In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats.

Satoh H, Ohtomo M, Ishikawa H, Kamma H, Yamashita YT, Ohtsuka M, Sekizawa K. Satoh H, et al. Among authors: ishikawa h. J Exp Ther Oncol. 2002 Jan-Feb;2(1):42-6. doi: 10.1046/j.1359-4117.2002.01005.x. J Exp Ther Oncol. 2002. PMID: 12415619

7

Liver metastasis at the time of initial diagnosis of lung cancer.

Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Kagohashi K, et al. Among authors: ishikawa h. Med Oncol. 2003;20(1):25-8. doi: 10.1385/MO:20:1:25. Med Oncol. 2003. PMID: 12665681

8

Time from finding abnormality on mass-screening to final diagnosis of lung cancer.

Kanashiki M, Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Kanashiki M, et al. Among authors: ishikawa h. Oncol Rep. 2003 May-Jun;10(3):649-52. Oncol Rep. 2003. PMID: 12684638

9

Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases.

Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M, Sekizawa K. Nakayama M, et al. Among authors: ishikawa h. Chest. 2003 Jun;123(6):2001-6. doi: 10.1378/chest.123.6.2001. Chest. 2003. PMID: 12796181

10

Is NSE truly a useful marker in NSCLC?

Ishikawa H, Satoh H, Sekizawa K. Ishikawa H, et al. Lung Cancer. 2004 May;44(2):267; author reply 269. doi: 10.1016/j.lungcan.2003.11.001. Lung Cancer. 2004. PMID: 15084392 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,410 results

Search Page